skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines

Journal Article · · Experimental Cell Research
 [1]; ;  [2];  [3]; ; ;  [1]
  1. Institute for Surgical Research, Philipps University of Marburg, Baldingerstrasse, 35043 Marburg (Germany)
  2. Institute of Pathology, Paracelsus Private Medical University of Salzburg, Salzburg (Austria)
  3. Institute for Pathology, Philipps University of Marburg, Marburg (Germany)

Inhibitors of protein deacetylases represent a novel therapeutic option for cancer diseases due to their effects on transcriptional regulation by interfering with histones acetylation and on several other cellular pathways. Recently, their ability to modulate several transcription factors and, interestingly, also co-factors, which actively participate in formation and modulation of transcription complexes was shown. We here investigate whether HMGA2 (High Mobility Group AT-2 hook), a nuclear non-histone transcriptional co-factor with known oncogenic properties, can be influenced by the novel pan-deacetylase inhibitor panobinostat (LBH589) in human hepatocellular carcinoma models. Panobinostat strongly downregulated HMGA2 in HepG2 and Hep3B cells; this effect was mediated by transcriptional upregulation and promotion of the maturation of the tumorsuppressor miRNA hsa-let-7b, which could inhibit HMGA2 expression via RNA interference pathways. siRNA knockdown of HMGA2 or transfection of hsa-let-7b mimicking oligonucleotides confirmed the role of HMGA2 in regulating cell proliferation and apoptosis in liver cancer cell lines. Co-incubation with panobinostat showed an additive effect on inhibition of cell proliferation using an impedance-based real-time cell analyzer. Treatment of HepG2 xenografts with panobinostat also led to a downregulation of HMGA2 in vivo. These findings show that pan-deacetylase inhibitors also modulate other signaling pathways and networks than histone modifications to influence cell fate. -- Highlights: Black-Right-Pointing-Pointer Panobinostat for the treatment of liver cancer. Black-Right-Pointing-Pointer Panobinostat meddles with miRNAs-dependent transcriptional and translational control. Black-Right-Pointing-Pointer Tumorsuppressor miRNA hsa-let-7b upregulation. Black-Right-Pointing-Pointer HMGA2 is downregulated via RNA interference pathways mediated by hsa-let-7b. Black-Right-Pointing-Pointer Panobinostat determines inhibition of proliferation via the axis hsa-let-7b - HMGA2.

OSTI ID:
22212594
Journal Information:
Experimental Cell Research, Vol. 318, Issue 15; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0014-4827
Country of Publication:
United States
Language:
English

Similar Records

MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA
Journal Article · Fri Sep 21 00:00:00 EDT 2012 · Biochemical and Biophysical Research Communications · OSTI ID:22212594

Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells
Journal Article · Fri Jan 04 00:00:00 EST 2013 · Biochemical and Biophysical Research Communications · OSTI ID:22212594

The histone demethylase LSD1 is required for estrogen-dependent S100A7 gene expression in human breast cancer cells
Journal Article · Fri Oct 19 00:00:00 EDT 2012 · Biochemical and Biophysical Research Communications · OSTI ID:22212594